Labcorp Holdings Inc. (LH) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Labcorp Holdings Inc. (LH) surged +2.20% to $368.16 as options desks priced 59% call premium vs. 41% put protection around the $361 max-pain magnet. Solid 29% profit margin (8% return on capital), mixed timing at 34x P/E—hold if owned, no rush to chase.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Charles River Laboratories International has become a talking point after a sharp multi‑year rally, which naturally raises a harder question for you as an investor: Is the current share price still grounded in the cash f
The fair value estimate for Labcorp Holdings has been adjusted from US$344.25 to US$354.50, a move of about US$10.25 that reflects updated analyst work after the latest Q3 review. External analysts have gone further, wit
Labcorp Holdings (NYSE: LH) partnered with Waters Corporation to deploy the BD Onclarity HPV Assay across its national laboratory network. The BD Onclarity HPV Assay rollout is designed to broaden access to advanced cerv
Labcorp stock barely flinched after its Q3 2026 release, ticking around 0.6% higher near US$362 even as the company posted a muscular quarter. Revenue reached about US$3.8b and adjusted earnings per share jumped to US$4.
UBS analyst Kevin Caliendo maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $380 to $420.
Barclays analyst Luke Sergott maintains Labcorp Holdings (NYSE:LH) with a Equal-Weight and raises the price target from $330 to $380.
Truist Securities analyst David Macdonald maintains Labcorp Holdings (NYSE:LH) with a Buy and raises the price target from $365 to $395.
Labcorp Holdings raised guidance and shares surged, but valuation looks stretched. Read more on LH stock here.
Baird analyst Eric Coldwell maintains Labcorp Holdings (NYSE:LH) with a Outperform and raises the price target from $361 to $396.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +7.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LH. Explore sector supply chains on /butterfly.
Why LH Stock surged +2.20% Today — RQD Quant Desk Flash. Solid 29% profit margin (8% return on capital), mixed timing at 34x P/E—hold if owned, no rush to chase.